In this study, we have investigated the synthesis of nanoparticles of hydroxyapatite (HAp) and hydroxyapatite coated with chitosan (HAp/Ch) and the chitosan-poly-d,l-lactide-co-glycolide polymer blend (HAp/Ch-PLGA) as an organ-targeting system. We have examined and defined the final destination, as well as the dynamics and the pathways of the synthesized particles following intravenous administration in vivo.
The XRD, ZP, FT-IR and SEM analyses have confirmed that the hydroxyapatite nanoparticles with d50 = 72 nm are coated with polymers. Radioactive 125-Iodine (125I), a low energy gamma emitter, was used to develop a novel in situ method for the radiolabeling of particles and investigation of their biodistribution. 125I-labeled particles exhibited high stability in saline and serum over the second day, which justified their use in the following in vivo studies.
The biodistribution of 125I-labeled particles after intravenous injection in rats differed significantly: HAp particles... mostly targeted the liver, HAp/Ch the spleen and the liver, while HAp/Ch-PLGA targeted the lungs. Twenty-four hours post injection, HAp particles were excreted completely, while both 125I-HAp/Ch and 125I-HAp/Ch-PLGA were retained in the body for a prolonged period of time with more than 20% of radioactivity still found in different organs.
Keywords:
nano hydroxyapatite / chitosan / organ targeting / in situ 125I-labeling / biodistribution
Source:
Materials Science and Engineering: C, 2014, 43, 439-436
TY - JOUR
AU - Ignjatović, Nenad
AU - Vranješ Đurić, Sanja
AU - Mitić, Žarko
AU - Janković, Drina
AU - Uskoković, Dragan
PY - 2014
UR - http://dais.sanu.ac.rs/123456789/539
AB - In this study, we have investigated the synthesis of nanoparticles of hydroxyapatite (HAp) and hydroxyapatite coated with chitosan (HAp/Ch) and the chitosan-poly-d,l-lactide-co-glycolide polymer blend (HAp/Ch-PLGA) as an organ-targeting system. We have examined and defined the final destination, as well as the dynamics and the pathways of the synthesized particles following intravenous administration in vivo.
The XRD, ZP, FT-IR and SEM analyses have confirmed that the hydroxyapatite nanoparticles with d50 = 72 nm are coated with polymers. Radioactive 125-Iodine (125I), a low energy gamma emitter, was used to develop a novel in situ method for the radiolabeling of particles and investigation of their biodistribution. 125I-labeled particles exhibited high stability in saline and serum over the second day, which justified their use in the following in vivo studies.
The biodistribution of 125I-labeled particles after intravenous injection in rats differed significantly: HAp particles mostly targeted the liver, HAp/Ch the spleen and the liver, while HAp/Ch-PLGA targeted the lungs. Twenty-four hours post injection, HAp particles were excreted completely, while both 125I-HAp/Ch and 125I-HAp/Ch-PLGA were retained in the body for a prolonged period of time with more than 20% of radioactivity still found in different organs.
PB - Elsevier
T2 - Materials Science and Engineering: C
T1 - Investigating an organ-targeting platform based on hydroxyapatite nanoparticles using a novel in situ method of radioactive 125Iodine labeling
SP - 439
EP - 436
VL - 43
DO - 10.1016/j.msec.2014.07.046
ER -
@article{
author = "Ignjatović, Nenad and Vranješ Đurić, Sanja and Mitić, Žarko and Janković, Drina and Uskoković, Dragan",
year = "2014",
url = "http://dais.sanu.ac.rs/123456789/539",
abstract = "In this study, we have investigated the synthesis of nanoparticles of hydroxyapatite (HAp) and hydroxyapatite coated with chitosan (HAp/Ch) and the chitosan-poly-d,l-lactide-co-glycolide polymer blend (HAp/Ch-PLGA) as an organ-targeting system. We have examined and defined the final destination, as well as the dynamics and the pathways of the synthesized particles following intravenous administration in vivo.
The XRD, ZP, FT-IR and SEM analyses have confirmed that the hydroxyapatite nanoparticles with d50 = 72 nm are coated with polymers. Radioactive 125-Iodine (125I), a low energy gamma emitter, was used to develop a novel in situ method for the radiolabeling of particles and investigation of their biodistribution. 125I-labeled particles exhibited high stability in saline and serum over the second day, which justified their use in the following in vivo studies.
The biodistribution of 125I-labeled particles after intravenous injection in rats differed significantly: HAp particles mostly targeted the liver, HAp/Ch the spleen and the liver, while HAp/Ch-PLGA targeted the lungs. Twenty-four hours post injection, HAp particles were excreted completely, while both 125I-HAp/Ch and 125I-HAp/Ch-PLGA were retained in the body for a prolonged period of time with more than 20% of radioactivity still found in different organs.",
publisher = "Elsevier",
journal = "Materials Science and Engineering: C",
title = "Investigating an organ-targeting platform based on hydroxyapatite nanoparticles using a novel in situ method of radioactive 125Iodine labeling",
pages = "439-436",
volume = "43",
doi = "10.1016/j.msec.2014.07.046"
}
Ignjatović N, Vranješ Đurić S, Mitić Ž, Janković D, Uskoković D. Investigating an organ-targeting platform based on hydroxyapatite nanoparticles using a novel in situ method of radioactive 125Iodine labeling. Materials Science and Engineering: C. 2014;43:439-436
Ignjatović, N., Vranješ Đurić, S., Mitić, Ž., Janković, D.,& Uskoković, D. (2014). Investigating an organ-targeting platform based on hydroxyapatite nanoparticles using a novel in situ method of radioactive 125Iodine labeling.
Materials Science and Engineering: CElsevier., 43, 439-436.
https://doi.org/10.1016/j.msec.2014.07.046
Ignjatović Nenad, Vranješ Đurić Sanja, Mitić Žarko, Janković Drina, Uskoković Dragan, "Investigating an organ-targeting platform based on hydroxyapatite nanoparticles using a novel in situ method of radioactive 125Iodine labeling" 43 (2014):439-436,
https://doi.org/10.1016/j.msec.2014.07.046 .
